BCR-ABL1 compound mutations in tyrosine kinase inhibitor–resistant CML: frequency and clonal relationships
Top Cited Papers
Open Access
- 17 January 2013
- journal article
- Published by American Society of Hematology in Blood
- Vol. 121 (3), 489-498
- https://doi.org/10.1182/blood-2012-05-431379
Abstract
BCR-ABL1 compound mutations can confer high-level resistance to imatinib and other ABL1 tyrosine kinase inhibitors (TKIs). The third-generation ABL1 TKI ponatinib is effective against BCR-ABL1 point mutants individually, but remains vulnerable to certain BCR-ABL1 compound mutants. To determine the frequency of compound mutations among chronic myeloid leukemia patients on ABL1 TKI therapy, in the present study, we examined a collection of patient samples (N = 47) with clear evidence of 2 BCR-ABL1 kinase domain mutations by direct sequencing. Using a cloning and sequencing method, we found that 70% (33/47) of double mutations detected by direct sequencing were compound mutations. Sequential, branching, and parallel routes to compound mutations were common. In addition, our approach revealed individual and compound mutations not detectable by direct sequencing. The frequency of clones harboring compound mutations with more than 2 missense mutations was low (10%), whereas the likelihood of silent mutations increased disproportionately with the total number of mutations per clone, suggesting a limited tolerance for BCR-ABL1 kinase domain missense mutations. We conclude that compound mutations are common in patients with sequencing evidence for 2 BCR-ABL1 mutations and frequently reflect a highly complex clonal network, the evolution of which may be limited by the negative impact of missense mutations on kinase function.Keywords
This publication has 38 references indexed in Scilit:
- Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaNew England Journal of Medicine, 2010
- Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid LeukemiaThe New England Journal of Medicine, 2010
- Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasmsBlood, 2010
- Identifying cancer driver genes in tumor genome sequencing studiesBioinformatics, 2010
- Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?Blood, 2009
- Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutationsBlood, 2009
- The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-upBlood, 2009
- AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based ResistanceCancer Cell, 2009
- The cancer genomeNature, 2009
- Activity of Bosutinib, Dasatinib, and Nilotinib Against 18 Imatinib-Resistant BCR/ABL MutantsJournal of Clinical Oncology, 2009